Zhuhai Huitongda Medicine Co., Ltd.

Bilastine orally disintegrating tablets (specification: 10 mg) developed by Zhuhai Huitongda Pharmaceutical Co., Ltd. were used as the test preparation, and Bilastine orally disintegrating tablets (trade name: Bilaxten®, specification: 10 mg) produced by FAES FARMA, S.A. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration under fasting conditions were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety of the two preparations in healthy humans was evaluated.

Primary study objective: To compare the effectiveness of loxoprofen sodium patch of Zhuhai Huitongda Pharmaceutical Co., Ltd. and the original research in the treatment of knee osteoarthritis. Secondary objective: To evaluate the safety of loxoprofen sodium patch in patients with knee osteoarthritis.

The diclofenac diethylamine emulsion produced by Zhuhai Huitongda Pharmaceutical Co., Ltd. was used as the test preparation, and the diclofenac diethylamine emulsion certified by GSK Consumer Healthcare Schweiz AG was used as the reference preparation for human bioequivalence evaluation.